Antihistamine Drugs Market Research Report - Forecast Till 2030

Antihistamine Drugs Market share, growth and trends analysis By Type (Sedating, Non-Sedating), Route of Administration (Oral Route, Parenteral Route, Rectal Route), Indication (Allergy, Urticaria, Dermatitis), End User (Hospitals, Clinics, Pharmaceutical Companies) - Forecast Till 2030

ID: MRFR/Pharma/2913-HCR | December 2022 | Region: Global | 206 Pages         

Antihistamine Drugs Market

Antihistamine drugs market is expected to grow USD 238.65 million at a CAGR 10.90% during the forecast period 2022-2030.

Segmentation

By Type Sedating Non-Sedating
By Route of Administration Oral Route Parenteral Route Rectal Route
By Indication Allergy Urticaria Dermatitis
By End User Hospitals Clinics Pharmaceutical Companies

Key Players

  • Johnson & Johnson Consumer Inc. (U.S.)
  • Sanofi (France)
  • Bayer AG (Germany)
  • Pfizer (U.S.)
  • CVS pharmacy (U.S.)
  • Merck
  • Sharp & Dohme Corp

Drivers

  • High rates of allergic rhinitis
  • Increasing awareness regarding treatments available for allergy
Speak to Analyst Request a Free Sample

Antihistamine Market Overview


The antihistamine market is expected to gain a market value of USD 280 million by 2030 at a CAGR of 9.8% from 2022-2030.


Antihistamine is a drug that blocks histamine, an inflammatory chemical in the body. Histamine causes sneezing, runny nose, and watery eyes. It can treat allergies (such as hay fever), chronic obstructive pulmonary disease, asthma, and other diseases. It can also reduce the risk of strokes in patients with high blood pressure.


The major factors influencing the antihistamine drugs market are the growing prevalence of allergic reactions and allergies across the globe and increasing awareness in people about treating several allergic reactions. Furthermore, allergy treatments are expected to increase in demand due to the changing lifestyle and novel drug therapies. There is a large market for these treatments and an increase in population. However, the expiration of patented drugs and the introduction of generic versions of medications and side effects from treatment are expected to moderate the market growth during the forecast period. According to the American College of Allergy, Asthma and Immunology (ACAAI), allergic rhinitis (AR) has increased in the last three decades. In the US and Europe, more than 40% of the population is sensitive to inhalant allergens. The increased prevalence may be related to intensifying air pollution levels.


COVID-19 Analysis


The COVID-19 pandemic positively impacted the sales of nasal antihistamines due to the most effective and popular mode of administration of nasal drugs. However, closed transnational borders, supply distribution channels, shortage of stock, and lockdown restrictions impacted sales of antihistamines to some extent.


According to forecasts from FMI, the COVID-19 market will recover in the next few years. This is accredited to the increasing demand for nasal sprays and more people relying on this treatment themselves. Amid transformations in healthcare, these trends are anticipated to continue, shaping the demand outlook positively.

Segments
                                                                                                                                    

The market is segmented on the basis of types which includes sedating and non-sedating antihistamines. Sedating antihistamines are further sub-segmented into brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, carbinoxamine and others. Non-sedating antihistamines are further sub-segmented into fexofenadine, loratadine, loratadine odt, and others.


On the basis of route of administration, the antihistamine drugs market is segmented into oral route, parenteral route and rectal route. Parenteral route segmented is further sub-segmented into intramuscular, subcutaneous and intravenous route.


On the basis of indication, the market is segmented into allergy, urticaria, dermatitis, and others. And on the basis of end users, the market is segmented into hospitals, clinics, pharmaceutical companies and others.

Regional Analysis                 


The American region accounts for the largest share of the global market due to rising prevalence of allergy rhinitis and rising demand for diagnosis and treatment of allergic disease. According to the American College of Allergy Asthma and Immunology, allergic asthma, food allergy, and eczema are the most common types of allergies found in the U.S.


Europe is the second largest market that holds a noticeable share of the antihistamine drugs market. According to the European Academy of Allergy and Clinical Immunology (EAACI), more than 50% of all Europeans will suffer from allergy in coming years.


In Asia Pacific, increase in the demand for drugs for the treatment of allergies and skin diseases drive the antihistamine drugs market growth. There has been a rise in the number of dermatology clinics across Asia Pacific from past few years. High rates of allergic rhinitis and increasing awareness regarding treatments available for allergy is poised to drive the growth of market in Asia Pacific.


The Middle East & Africa, the market shows steady but positive growth due to the rising prevalence of nasal allergies.


Recent Developments



  • In June 2021, the FDA approved Bayer AG's Astepro, used for seasonal and perennial allergies, for non-prescription use through a partial prescription to non-prescription switch. This FDA approval has run to individuals having the accessibility to a safe, effective nasal antihistamine without demanding the assistance of a healthcare provider.

  • In May 2021, Glenmark Pharma launched a new nasal spray called Ryaltris in India. Glenmark is a leader in the respiratory segment and was the first to introduce branded versions at an affordable price in India.

  • In July 2019, Mylan signed an agreement with Pfizer, which will merge with Mylan to become Viatris, a new global pharmaceutical corporation.



Key Players in the Antihistamine drugs Market   
     
                       
Some of the key players in market are Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)


Intended Audience:




  • Antihistamine drug manufacturers




  • Antihistamine drug suppliers




  • Medical research laboratories




  • Research and Development (R&D) Companies




  • Market Research and Consulting Service Providers




  • Potential Investors





Report Scope:

Report Attribute/Metric Details
  Market Size   238.65 Million
  CAGR   10.90%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Route of Administration, Indication, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • High rates of allergic rhinitis
  • Increasing awareness regarding treatments available for allergy


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The Antihistamine Drug Market valuation would be USD 238.65 Million 2030.

    The CAGR would be 1090% during the forecast period of 2022 to 2030.

    The players are Sanofi (France), Johnson & Johnson Consumer Inc. (U.S.), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), Bayer AG (Germany), and Prestige Brands Holdings, Inc. (U.S.).

    The types are sedating and non-sedating antihistamines.

    The types are allergy, urticaria, dermatitis, and others.